TTOO) decreased 7.49% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 74.29% over the past year to ($0.09), which beat the
TTOO) decreased 14.3% in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 74.29% over the past year to ($0.09), which beat the estimate of ($0.15).
Revenue of $2,552,000 up by 41.46% from the same period last year, which beat the estimate of $2,370,000.
Looking Ahead
T2 Biosystems hasn’t issued any earnings guidance for the time being.
T2 Biosystems hasn’t issued any revenue guidance for the time being.
Details Of The Call
Date: Aug 11, 2020
View more earnings on TTOO” data-reactid=”26″>View more earnings on TTOO
Time: 04:30 PM
http://public.viavid.com/player/index.php?id=140859” data-reactid=”28″>ET Webcast URL: http://public.viavid.com/player/index.php?id=140859
Price Action
52-week high: $3.21
52-week low: $0.23
Price action over last quarter: Up 242.86%
Company Description
T2 Biosystems Inc provides rapid in vitro diagnostic tests to hospitals and laboratories. Its core technology is T2 Magnetic Resonance (T2MR) technology, which can detect a variety of molecular targets directly from whole blood. T2MR technology enables the T2Dx system, which is fully automated from patient sample to result for its panels focused on bacterial and fungal infections that could cause sepsis, and its pipeline panel for Lyme disease.
View Article Origin Here
